About the Ypsomed Group

The Ypsomed Group is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years’ experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1500 employees.

Ypsomed Diabetes Care

With its mylife Diabetescare brand, Ypsomed operates successfully in the B2C business with products and services for people with diabetes mellitus. The product portfolio includes: insulin pumps, infusion sets, pen needles, blood glucose monitoring systems and other diabetes supplies. Products are distributed via Ypsomed’s subsidiaries to hospitals, doctors, pharmacies and patients, and via distributors (pen needles).

Diabetes: A global disease with pandemic growth predicted in the coming 20 years. Currently diabetes is growing at approximately 9% p. a. Due to that fact Ypsomed is expanding its network of subsidiaries consequently with its outstanding product portfolio.

Ypsomed Delivery Systems

Our pharmaceutical and biotech customers purchase injection systems and corresponding services under the YDS brand, Ypsomed Delivery Systems. They do this via the industry leader, as Ypsomed is the world’s largest developer and manufacturer of pens and autoinjectors with which patients can administer their liquid medication subcutaneously themselves.

Trends for future drugs: Drugs are becoming more speci-fic, e.g. in the treatment of autoimmune diseases. Insteadof a generic drug (e.g. Humira®), a large number of new,very specific drugs come onto the market. New drugs forAlzheimer's disease, obesity and rare diseases are being developed. Cancer drugs are also becoming more specific. Efforts to develop active ingredients for subcutaneousinjection open up opportunities for self-medication with auto- and patch injectors.


In the 2018/19 financial year, our sales will be in the same order of magnitude as in the financial year 2017/18. At the EBIT level, we expect a result of CHF 73 million for the current financial year.

Key financial figures: multi-year overview

In thousand CHF 2017/18 2016/17 2015/16 2014/15
Sales of goods and services 466119 389 555 336 922 306 632
Gross Profit 139825 125 478 103 187 85 850
Operating Profit 61070 55 298 44 435 28 546
Net Profit 52060 46 247 35 812 19 395
EBITDA1 95539 87 763 73 270 57 369
Cash flow from operating activities 53269 75 064 76 687 41 381
Year-end headcount 1451 1 314 1 166 1 050

1 Operating profit before depreciation and Amortisation.